MX2022014725A - Estrategias de tratamiento del cáncer mediante el uso de vectores de arenavirus. - Google Patents
Estrategias de tratamiento del cáncer mediante el uso de vectores de arenavirus.Info
- Publication number
- MX2022014725A MX2022014725A MX2022014725A MX2022014725A MX2022014725A MX 2022014725 A MX2022014725 A MX 2022014725A MX 2022014725 A MX2022014725 A MX 2022014725A MX 2022014725 A MX2022014725 A MX 2022014725A MX 2022014725 A MX2022014725 A MX 2022014725A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment strategies
- cancer treatment
- arenavirus vectors
- arenavirus particles
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063032362P | 2020-05-29 | 2020-05-29 | |
| US202163173155P | 2021-04-09 | 2021-04-09 | |
| US202163175842P | 2021-04-16 | 2021-04-16 | |
| PCT/EP2021/062728 WO2021239471A1 (en) | 2020-05-29 | 2021-05-12 | Cancer treatment strategies using arenavirus vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014725A true MX2022014725A (es) | 2023-02-09 |
Family
ID=75914543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014725A MX2022014725A (es) | 2020-05-29 | 2021-05-12 | Estrategias de tratamiento del cáncer mediante el uso de vectores de arenavirus. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230346906A1 (https=) |
| EP (1) | EP4157342A1 (https=) |
| JP (1) | JP2023527083A (https=) |
| KR (1) | KR20230046278A (https=) |
| AU (1) | AU2021282287A1 (https=) |
| BR (1) | BR112022024404A2 (https=) |
| CA (1) | CA3184791A1 (https=) |
| CR (1) | CR20220602A (https=) |
| IL (1) | IL298420A (https=) |
| MX (1) | MX2022014725A (https=) |
| PE (1) | PE20240647A1 (https=) |
| WO (1) | WO2021239471A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2604695B1 (en) | 2007-12-27 | 2022-11-16 | Universität Zürich | Replication-defective arenavirus vectors |
| CN115058452A (zh) | 2013-12-03 | 2022-09-16 | 霍欧奇帕生物科技有限公司 | Cmv疫苗 |
| EP3307308A2 (en) | 2015-06-10 | 2018-04-18 | Hookipa Biotech AG | Hpv vaccines |
| WO2023152116A1 (en) * | 2022-02-08 | 2023-08-17 | Hookipa Biotech Gmbh | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| AU2024343172A1 (en) | 2023-09-15 | 2026-03-05 | Gilead Sciences, Inc. | Arenavirus formulations, methods and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3218504T (lt) | 2014-11-13 | 2020-09-10 | Université De Geneve | Trijų segmentų arenavirusai kaip vakcinos vektoriai |
| EP3307308A2 (en) * | 2015-06-10 | 2018-04-18 | Hookipa Biotech AG | Hpv vaccines |
| RS63546B1 (sr) | 2015-11-12 | 2022-09-30 | Hookipa Biotech Gmbh | Čestice arenavirusa kao vakcine protiv kancera |
| US20190135875A1 (en) | 2016-05-18 | 2019-05-09 | Hookipa Biotech Gmbh | Tri-segmented pichinde viruses as vaccine vectors |
| AU2018247958A1 (en) * | 2017-04-07 | 2019-10-10 | Hookipa Biotech Gmbh | Arenavirus particles to treat solid tumors |
-
2021
- 2021-05-12 MX MX2022014725A patent/MX2022014725A/es unknown
- 2021-05-12 JP JP2022573287A patent/JP2023527083A/ja active Pending
- 2021-05-12 KR KR1020227044315A patent/KR20230046278A/ko active Pending
- 2021-05-12 BR BR112022024404A patent/BR112022024404A2/pt unknown
- 2021-05-12 AU AU2021282287A patent/AU2021282287A1/en active Pending
- 2021-05-12 PE PE2022002786A patent/PE20240647A1/es unknown
- 2021-05-12 US US17/928,098 patent/US20230346906A1/en active Pending
- 2021-05-12 WO PCT/EP2021/062728 patent/WO2021239471A1/en not_active Ceased
- 2021-05-12 EP EP21725519.9A patent/EP4157342A1/en active Pending
- 2021-05-12 IL IL298420A patent/IL298420A/en unknown
- 2021-05-12 CR CR20220602A patent/CR20220602A/es unknown
- 2021-05-12 CA CA3184791A patent/CA3184791A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL298420A (en) | 2023-01-01 |
| JP2023527083A (ja) | 2023-06-26 |
| AU2021282287A1 (en) | 2023-01-05 |
| WO2021239471A9 (en) | 2022-01-13 |
| KR20230046278A (ko) | 2023-04-05 |
| EP4157342A1 (en) | 2023-04-05 |
| WO2021239471A1 (en) | 2021-12-02 |
| CR20220602A (es) | 2023-05-16 |
| PE20240647A1 (es) | 2024-04-04 |
| BR112022024404A2 (pt) | 2023-02-07 |
| CA3184791A1 (en) | 2021-12-02 |
| US20230346906A1 (en) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022014725A (es) | Estrategias de tratamiento del cáncer mediante el uso de vectores de arenavirus. | |
| MX2021001883A (es) | Virus recombinantes del mixoma y usos de los mismos. | |
| EP4431109A3 (en) | Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer | |
| AU2016293674B2 (en) | A novel approach for treatment of cancer using immunomodulation | |
| MX2022009100A (es) | Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer. | |
| MY191040A (en) | Therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| MX2023000197A (es) | Arn terapeutico para el cancer positivo para vph. | |
| ZA202206485B (en) | Use of bi853520 in cancer treatment | |
| SG10201811190SA (en) | Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon | |
| WO2021222476A3 (en) | High efficiency gene delivery system | |
| PH12021550661A1 (en) | Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy | |
| MX2025008524A (es) | Métodos y composiciones para la terapia combinada | |
| ZA202300222B (en) | Anti-αlpha-4-βeta-7 antibodies | |
| WO2019204332A3 (en) | Pak4 inhibitors and methods of use | |
| AU2020327022A8 (en) | Method of treating cancer | |
| MX2022008532A (es) | Inhibidores de hidrocarburo de arilo (ahr) y usos de estos. | |
| WO2021174195A3 (en) | Use of thyromimetics for the treatment of cancer | |
| PH12023553212A1 (en) | Improved methods of treatment using immunogenic peptides | |
| JOP20210225A1 (ar) | تركيبة دوائية لعلاج الأورام الخبيثة ذات الخلايا البائية | |
| MY194694A (en) | Method and composition for treating cancer or skin lesion using a vaccine | |
| MX2021012398A (es) | Metodos de terapia antitumoral. | |
| WO2020212514A8 (en) | Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer | |
| MY210133A (en) | Compositions and methods for controlled ovarian stimulation | |
| MX2024005084A (es) | Tratamientos administrados de manera subcutanea para enfermedad de parkinson avanzada. | |
| EP4656657A3 (en) | Therapeutic or prophylactic agent for htlv-1-associated myelopathy (ham), and method for treating ham |